VC2

First Full Spectrum 5G Hospital at VA Palo Alto Health Care System Will Empower Unprecedented Care for Veterans

Retrieved on: 
Monday, July 24, 2023
Advertising, CT, Partnership, Public sector, Veterans' affairs, Verizon Business, 3D, Independent agencies of the United States government, Veteran, United States Department of Veterans Affairs, Government, VR, MRI, Physician, Veterans Health Administration, VC2, Knowledge, AR, Safety, Pharmaceutical industry, Medical imaging, VA Palo Alto Health Care System, Verizon Communications

WASHINGTON, July 24, 2023 (GLOBE NEWSWIRE) -- Verizon Business, in partnership with the VA Palo Alto Health Care System, today announced the deployment of a full spectrum private 5G network.

Key Points: 
  • WASHINGTON, July 24, 2023 (GLOBE NEWSWIRE) -- Verizon Business, in partnership with the VA Palo Alto Health Care System, today announced the deployment of a full spectrum private 5G network.
  • These in-building systems are integrated with Verizon 5G rooftop macro sites at VA Palo Alto that provide 5G services to the exterior of the campus.
  • Combined, these 5G systems utilize all three 5G frequency bands servicing the VA Palo Alto campus to deliver a next generation, campus-wide, full-spectrum, hybrid commercial and private 5G environment that will expand the 5G capabilities.
  • “The work VA Palo Alto Health Care System is doing is a shining example of what the partnership between the VA and Verizon makes possible,” said Kyle Malady, Verizon Business CEO.

Rational Vaccines' RVX1001 Vaccine Candidate Protects Against HSV Ocular Infection in vivo

Retrieved on: 
Tuesday, December 28, 2021
People, Antibody, Fissure, Company, World, Louisiana State University, Blister, Immune system, School, Fever, Department, VC2, WHO, Infection, HK, Herpes simplex keratitis, LSU, Vaccination, Myalgia, Vaccine, Virology, UC Davis School of Veterinary Medicine, Patient, Severe cognitive impairment, McQuillan, LSU School of Music, HSV-1, Alzheimer's disease, HSV-2, HSV, Mouse, Research, Prevalence, Virus, Veterinary medicine, Diagnosis, Cornea, Frontiers, Keratitis, Neutrophil, Chills, Genital herpes, Multimedia, Erythema, Dementia, Disease, Social stigma, Biotechnology, MRCVS, World Health Organization, BVM, Doctor of Philosophy, Simplex, Ulcer, Immunology

Dr. Kousoulas stated, "These data provide in vivo proof of concept for the prophylactic treatment of herpetic keratitis with our HSV-1 vaccine.

Key Points: 
  • Dr. Kousoulas stated, "These data provide in vivo proof of concept for the prophylactic treatment of herpetic keratitis with our HSV-1 vaccine.
  • Results showed that RVX1001 administered prophylactically protected mice against lethal ocular HSV-1 challenge and the development of herpetic keratitis.
  • Herpetic keratitis induced by herpes simplex virus type 1 (HSV-1) ocular infection is a leading infectious cause of blindness.
  • Intramuscular Vaccination With the HSV-1(VC2) Live-Attenuated Vaccine Strain Confers Protection Against Viral Ocular Immunopathogenesis Associated With T Cell Intracorneal Infiltration.